Abstract: Peptides that generate an immune response to glioma-related H3.3 proteins and methods of their use are provided.

Abstract: The present disclosure relates to methods and compositions comprising naturally occurring light absorbing molecules for preventing damages from light exposure. Specific embodiments of this disclosure include fluorescent proteins from Brachiostoma lanceolatum.

Abstract: A system and method for facilitating machine interpretation of potentially ambiguous input, such as natural language. An example method includes constructing an ontology based on a database schema, wherein the ontology includes one or more indications of relationship strengths characterizing two or more entities of the ontology; collecting context information pertaining to a relevant domain; receiving the potentially ambiguous input; employing the input and the ontology to estimate a meaning of the input using the context information, the one or more indications of relationship strength, and an estimation of a probability that one or more portions of the natural language input refer to a particular entity.

Abstract: The invention provides genetically modified non-human animals that express chimeric human/non-human T cell co-receptor polypeptides (e.g., CD4, CD8?, CD8?), as well as embryos, cells, and tissues comprising the same. Also provided are constructs for making said genetically modified animals and methods of making the same.

Abstract: In certain embodiments, the present disclosure provides compounds and methods of increasing the amount or activity of a target protein in a cell. In certain embodiments, the compounds comprise a translation suppression element inhibitor. In certain embodiments, the translation suppression element inhibitor is a uORF inhibitor. In certain embodiments, the uORF inhibitor is an antisense compound.

Abstract: The invention relates to methods and devices for quantitative determination of bacteria.

Abstract: Methods and devices can enhance language processing in an autism spectrum disorder (ASD) individual through auditory manipulation of an auditory stream. The auditory stream is received and includes an acoustic stimulus perceptually representing an object. An acoustic manipulation parameter for a predetermined acoustic detail characteristic is selected. The predetermined acoustic detail characteristic is associated with the ASD individual and is based on a measured language processing capability of the ASD individual. The auditory stream is modified based on the selected parameter, to reduce the predetermined acoustic detail characteristic while preserving a lexicality of the stimulus, such that the reduced acoustic detail characteristic enhances perception of the object by the ASD individual even when the stimulus includes two or more acoustically distinct stimuli each perceptually representing the object. The modified auditory stream is output to the ASD individual via at least one loudspeaker.

Abstract: Presented herein are methods and compositions for tagmentation of nucleic acids. The methods are useful for generating tagged DNA fragments that are qualitatively and quantitatively representative of the target nucleic acids in the sample from which they are generated.

Abstract: In some aspects, the invention relates to methods for determining the proportion of intact, hypermutated, deleted, and/or defective proviruses in a sample of nucleic acids, e.g., a sample obtained from a subject. The subject may be a human subject. The virus may be HIV.

Abstract: Disclosed are methods and pharmaceutical compositions for modulating one or more steroidal receptor activities. The methods typically utilize and the pharmaceutical compositions typically include one or more substituted phenyl aziridine precursors, their respective aziridines, analogs thereof, derivatives thereof, or pharmaceutically acceptable salts thereof such as CpdA. The methods and compositions may be used for treating diseases, disorders, and conditions associated with glucocorticoid receptor activity, androgen receptor activity, or both, such as cancers, acne vulgaris, and alopecia.

Abstract: Provided is a method of application security vulnerability evaluation based on tree boosting and a readable medium and an apparatus for performing the same. The method of application security vulnerability evaluation based on tree boosting includes the step of generating an API classifier which classifies an input API as benign or malicious using a tree boosting-based algorithm, the step of calculating security vulnerability score of API using the API classifier, and the step of classifying a target application as a malicious application or a benign application according to the security vulnerability score of API used in the target application.

Abstract: Disclosed herein are methods for assaying a biological sample from a subject by analyzing components of microvesicle fractions in aid of risk, diagnosis, prognosis or monitoring of, or directing treatment of the subject for, a disease or other medical condition in the subject. Also disclosed are methods of treatment and identifying biomarkers using a microvesicle fraction of a subject. Kits, pharmaceutical compositions, and profiles related to the methods are also disclosed.

Abstract: The present invention relates to antisense oligonucleotides that modulate the expression of and/or function of Sodium channel, voltage-gated, alpha subunit (SCNA), in particular, by targeting natural antisense polynucleotides of Sodium channel, voltage-gated, alpha subunit (SCNA). The invention also relates to the identification of these antisense oligonucleotides and their use in treating diseases and disorders associated with the expression of SCNA.

Abstract: The present invention provides novel mutations of the CFTR gene related to cystic fibrosis or to conditions associated with cystic fibrosis. Also provided are probes for detecting the mutant sequences. Methods of identifying if an individual has a genotype containing one or more mutations in the CFTR gene are further provided.

Abstract: Presented herein are live-attenuated viruses and methods of generating thereof from a parental virus through a plurality of nucleotide substitutions in the viral genome. The nucleotide substitutions result in a change in codon usage bias within codons of one or more protein encoding sequences and no change in amino acid sequences of the proteins. The live-attenuated viruses display unaltered replication in avian hosts for propagation, but attenuated replication in mammalian hosts, when compared to the replication of the parental virus. The live-attenuated viruses in a form of improved vaccines can be used to elicit protective immune responses.

Abstract: The present invention relates to a method for preventing cancerization of normal cells due to low-dose irradiation. The method enables effective prevention of cancerization of normal cells by means of low-dose radiation which is innocuous to a subject.

Abstract: The present invention relates to the use of a casein hydrolysate as an antiviral agent for the treatment of opportunistic virus infections, especially herpesvirus and human papillomavirus. This casein hydrolysate has an application in both the therapeutic treatment of established symptoms and the prevention of the infection or the reactivation of a latent infection by an opportunistic virus. The casein hydrolysate of the present invention is effective for the prevention of opportunistic virus infections in individuals with weakened immune system.

Abstract: Provided herein are products and processes for the quantitation of mitochondrial nucleic acid in a sample from a subject. In certain aspects are multiplex methods for determining dosage of mitochondrial nucleic acid relative to genomic nucleic acid for a sample from a subject including amplifying sets of mitochondrial polynucleotides and genomic polynucleotides from nucleic acid for a sample under amplification conditions. In certain aspects are multiplex methods for determining dosage of mitochondrial nucleic acid relative to genomic nucleic acid for a sample from a subject including amplifying sets of mitochondrial polynucleotides and amplifying sets of nuclear polynucleotides from nucleic acid for a sample under amplification conditions.

Abstract: Disclosed herein are antibodies capable of specifically binding to tenofovir (TFV), a key small molecule drug for both the treatment and prevention of HIV, and a competitive lateral flow assay that uses these antibodies to monitor urine samples for the presence of the drug. The assay can be deployed as a point-of-care device for adherence monitoring.

Abstract: Embodiments described herein relate generally to compositions that include a synthetic redox-active receptor, and in particular to compositions that include a boronic acid based synthetic redox-active receptor which can electrochemically sense a target analyte in a sample solution. In some embodiments, a synthetic redox-active receptor can have a composition of formula I: wherein the variables L, L?, R, R?, n and X? are described herein.

Abstract: The invention provides a high efficiency fluorescence in situ hybridization (FISH) method for detecting mutations on individual RNA transcripts, including both exonic and intronic RNA transcripts. In certain embodiments, the method is used to quantify allelic expression at the population and single cell level, and also to distinguish maternal chromosomes from paternal chromosomes in single cells.

Abstract: An image processing device and a program capable of extracting a cell region as a diagnosis target more accurately may be provided. An image processing device is characterized by: first extraction means (control unit 21) for extracting a candidate region from a form image representing a form of a cell in a tissue sample; acquisition means (control unit 21) for acquiring biological substance information on at least one kind of the biological substance from images representing expression of one or more kinds of biological substances in the tissue sample; and second extraction means (control unit 21) for extracting a diagnosis target region from the candidate region based on characteristic information indicating characteristics of the candidate region and/or the biological substance information.

Abstract: Disclosed herein is a novel method to fabricate magnetic silica nanomembranes using thin polymer cores based on silica deposition and self-wrinkling induced by thermal shrinkage. These micro- and nano-scale structures have vastly enlarged the specific area of silica, thus the magnetic silica nanomembranes can be used for solid phase extraction of nucleic acids. The magnetic silica nanomembranes are suitable for nucleic acid purification and isolation and demonstrated better performance than commercial particles in terms of nucleic acid recovery yield and integrity. In addition, the magnetic silica nanomembranes may have high nucleic acid capacity due to significantly enlarged specific surface area of silica. Methods of use and devices comprising the magnetic silica nanomembranes are also provided herein.

Abstract: Aspects of the present invention relate to compositions and methods for providing DNA fragments from a remote sample. In particular aspects a remote sample comprising DNA is provided, DNA is isolated from the remote sample, and the isolated DNA is treated in a way which allows differentiation of methylated and unmethylated cytosine. Additional, particular embodiments provide compositions and methods for methylation analysis of DNA derived from a remote sample. Other aspects provide for compositions and methods of whole genome amplification of bisulfite treated DNA. Other aspects provide methods for determining the presence or absence of methylation of at least one cytosine, or a series of cytosines in cis, in human DNA of a blood sample, a plasma sample, a serum sample or a urine sample from a human individual.

Abstract: The present invention relates to a novel antibody against HERV-K envelope that targets a conserved region not affected by glycosylation or by native conformation, and its use in diagnostics and/or in therapy.

Abstract: The present invention relates to probes and primers beneficial for conducting amplification assays, such as those including loop-mediated isothermal amplification reactions. Also described herein are methods for detecting targets using such probes and/or primers.

Abstract: Methods and devices are provided herein for identifying a cell population comprising an effector cell that exerts an extracellular effect. In one embodiment the method comprises retaining in a microreactor a cell population comprising one or more effector cells, wherein the contents of the microreactor further comprise a readout particle population comprising one or more readout particles, incubating the cell population and the readout particle population within the microreactor, assaying the cell population for the presence of the extracellular effect, wherein the readout particle population or subpopulation thereof provides a direct or indirect readout of the extracellular effect, and determining, based on the results of the assaying step, whether one or more effector cells within the cell population exerts the extracellular effect on the readout particle. If an extracellular effect is measured, the cell population is recovered for further analysis to determine the cell or cells responsible for the effect.

Abstract: A fluorescent probe for binding to and detection of AP sites of DNA includes the following formula: F-L-X where F is a fluorescent moiety, X is an aminooxy group (—ONH2), and L is a linker that links or couples the fluorescent moiety to the oxyamine.

Abstract: Provided herein is a method of sequencing hydroxymethyated cell-free DNA. In some embodiments, the method comprises adding an affinity tag to only hydroxymethyated DNA molecules in a sample of cfDNA, enriching for the DNA molecules that are tagged with the affinity tag; and sequencing the enriched DNA molecules.

Abstract: An analytical system that includes a flow cell, a liquid delivery component, a gas delivery component and a bubble generator component, wherein the liquid delivery component is configured to deliver liquid from one or more reservoirs to the bubble generator component, wherein the gas delivery component is configured to deliver gas from one or more source to the bubble generator component, and wherein the bubble generator component is configured to mix liquids from the liquid delivery component with gas from the gas delivery component to deliver a fluid foam to the inside of the flow cell, wherein the fluid foam includes bubbles of the gas in the liquid.

Abstract: A method of preparing an antibody therapeutic is provided comprising: (a) providing a dissociated cell sample from at least one solid tumor sample obtained from a patient; (b) loading the dissociated cell sample into a microfluidic device having a flow region and at least one isolation region fluidically connected to the flow region; (c) moving at least one B cell from the dissociated cell sample into at least one isolation region in the microfluidic device, thereby obtaining at least one isolated B cell; and (d) using the microfluidic device to identify at least one B cell that produces antibodies capable of binding to cancer cells. The cancer cells can be the patient's own cancer cells. Also provided are methods of treating patients, methods of labeling or detecting cancer, engineered T or NK cells comprising antibodies or fragments thereof, and engineered antibody constructs.

Abstract: A microcapsule composition comprising at least one polymer substantially disposed as a semi-permeable shell around an aqueous buffered solution and at least one agent, wherein the agent permeates the shell, and wherein the composition is suitable for delivery to a mammal. This invention also provides related compositions, products and methods.

Abstract: Provided herein are methods for selecting a drug therapy for a patient with cancer, such as colorectal cancer, pancreatic cancer, lung cancer or breast cancer. The method includes determining or measuring the level of RasGRP1 polynucleotide or polypeptide in a sample from the patient. Also provided herein are methods for determining the likelihood of a good prognosis for a patient with cancer. Additionally, provided herein are methods for predicting the likelihood of a negative clinical response to an anti-EGFR therapy in a subject with cancer.

Abstract: Disclosed are: a nucleotide sequence and an amino acid sequence for CDR3 region of T-cell receptor (TCR) gene of WT1-specific cytotoxic T-cell (CTL) for WT1 protein; a method for the detection or treatment of cancer using the nucleotide sequence or the amino acid sequence; and a chip, a primer set, a kit, an apparatus and the like for use in the detection of cancer, each of which comprises the nucleotide sequence or the amino acid sequence.

Abstract: Compositions and methods for the isolation of protein-nucleic acid complexes and microvesicles (collectively referred to as “bioparticles”) released by mammalian cells into body fluids or cell culture media are provided. Isolated bioparticles of the invention contain biological molecules that are useful as diagnostic/prognostic biomarkers or for identification of therapeutic targets (e.g., disease or disorder-associated miRNAs). The isolation of biological molecules as described herein results in purification and concentration of the molecules. Methods for producing bio fluids that are free of detectable bioparticles, that are largely depleted of bioparticles, or that possess a reduced concentration of bioparticles compared to a bio fluid starting material (collectively termed “bioparticle-depleted”) are also provided. Isolation of bioparticle-depleted biofluid is useful, e.g.

Abstract: Provided herein are methods, compositions and kits to extract and relatively enrich by physical separation or amplification short base pair nucleic acid in the presence of a high background of genomic material (e.g., host or maternal nucleic acids).

Abstract: The invention generally relates to methods for diagnosing autism spectrum disorders. In certain embodiments, the invention provides a method for diagnosing presence or increased risk of developing an autism spectrum disorder in a subject.

Abstract: The present invention provides immunoresponsive cells, including T cells, cytotoxic T cells, regulatory T cells, and Natural Killer (NK) cells, expressing at least one of an antigen recognizing receptor and one of a chimeric costimulatory receptor. Methods of using the immunoresponsive cell include those for the treatment of neoplasia and other pathologies where an increase in an antigen-specific immune response is desired.

Abstract: Provided is a use of a recombinant human calcineurin B subunit (rhCNB) in the preparation of a medicine for killing and/or inhibiting the gastric cancer.

Abstract: This disclosure is directed to structured compositions, including DNA-functionalized scaffolds, for drug capture, and methods and devices for sequestering chemotherapeutics from physiological fluids using the functionalized scaffolds.

Abstract: There are disclosed a method for determining binding constants between a substance or a substance mixture and a target, and a kit for carrying out the method according to the invention. The binding constants of the substance for the targets are determined by shifting the binding equilibrium. The concentrations of the immobilised and the dissolved target are varied and the affinities with the targets are determined by shifting the binding equilibria in the individual batches.

Abstract: Provided is a peptide fragment derived from secreted frizzled protein 5 (Sfrp5), i.e., a peptide fragment selected from the group consisting of the peptides as set forth in SEQ ID NOs: 1 to 9 and a cosmetic composition for skin-whitening and/or inhibiting skin pigmentation comprising the same as an active ingredient. The peptide fragment inhibits melanin formation in melanocytes, thereby having an inhibitory activity against skin pigmentation. Further provided is a reagent for researching or analyzing the inhibition of Wnt signaling pathways comprising the peptide fragment.

Abstract: The present invention relates to a primer for PCR obtained by, directly or through inosine as a linker, linking a complementary nucleotide sequence or a complementary nucleotide sequence including a mis-matched nucleotide sequence to the 5?-terminal of a forward or reverse primer; and to a PCR method including a step of mixing a nucleic acid template in a PCR composition including the primer and then performing PCR on the mixture. The primer for PCR of the present invention includes a complementary nucleotide sequence or a mis-matched nucleotide sequence in a complementary nucleotide sequence, which is linked to the 5?-terminal thereof directly or via a linker, thereby lowering the sensitivity increase due to the increase in amplification products and reducing non-specifically occurring reactions in PCR.

Abstract: The present invention relates to the field of epigenetics. More specifically, the present invention provides methods and compositions useful for predicting response to epigenetic drug therapy. As described herein, we have identified a unique signature termed AZA Immune gene set or AIM that differentiates patients with a low immune and high immune signature and is regulated by epigenetic drugs such as demethylating drugs, histone deacetylase inhibitors. In certain embodiments, patients with a high immune signature may benefit from immunotherapies such as anti PD1 or anti PDL1 antibodies or vaccines. In other embodiments, patients with a low immune signature or low AIM would be patients who would then benefit from treatment with epigenetic drugs and then subsequent immunotherapy.

Abstract: A method and an analysis system for testing a biological sample, nucleic-acid products being hybridized to capture molecules of a sensor apparatus at different temperatures.

Abstract: The present disclosure relates to the identification of genes and gene combinations that are correlated with patients having or being predisposed to developing pancreatic ductal adenocarcinoma (PDAC). In some instances, methods herein utilize panels of 5 or 10 genes to accurately diagnose PDAC, determine the likelihood of developing PDAC, or determine the severity/stages of PDAC. These panels may be used in a molecular diagnostic test.

Abstract: The present invention provides kits and methods for detecting peptides that change of the fluorescence of dyes upon binding to the dye. In addition, the invention provides methods for identifying said peptides.

Abstract: A method for sequencing a nucleic acid strand, comprising the steps of: providing a solution containing truncated strands having lengths different from one another terminating with a respective dideoxynucleotide from among ddATP, ddTTP, ddGTP, and ddCTP; functionalizing first masses by a donor molecule and second masses by an acceptor molecule such as to generate a light emission when they come into mutual contact; coupling a first mass to a first end of each truncated strand; coupling the second masses to a respective terminal dideoxynucleotide of each strand; applying an AC electrical field having variable frequencies that are such as to generate, on each second mass, a net movement directed towards the first mass; acquiring a plurality of light radiations for each frequency value; and associating each light radiation acquired to a respective dideoxynucleotide and, thus, to a respective nucleotide base.

Abstract: Biomaterials and methods and uses for repair or augmentation of tissues are provided. In particular, the invention provides a multi-layered, naturally occurring multi-axial oriented biomaterial comprising predominately type I collagen fibers. The invention further provides methods and uses for repair or augmentation of tissues using biomaterials of the invention.

Abstract: A method of transferring material from a first microfabricated device to a second microfabricated device. At least one magnetic bead is loaded into at least one microwell of the first microfabricated device, where a plurality of cells are cultivated. The second microfabricated device is positioned such that the at least one microwell of the first array of microwells is aligned with at least one microwell of the second array of microwells. A magnetic field is applied so as to move the at least one magnetic bead contained in the at least one microwell of the first microfabricated device into the at least one microwell of the second microfabricated device. In this manner, at least one cell from the plurality of cells in the at least one microwell of the first microfabricated device is transferred to the at least one microwell of the second microfabricated device.